Skip to main content
Clinical Trials/NL-OMON40846
NL-OMON40846
Withdrawn
Phase 3

Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack (RESUS-AMI) - RESUS-AMI

niversity college Cork, Centre for Research in Vascular Biology  Bio Sciences Institute0 sites15 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
acute myocardial infarction with LVEF< 30%
Sponsor
niversity college Cork, Centre for Research in Vascular Biology  Bio Sciences Institute
Enrollment
15
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
niversity college Cork, Centre for Research in Vascular Biology  Bio Sciences Institute

Eligibility Criteria

Inclusion Criteria

  • 1\. Age 18 \* 75
  • 2\. Subject presents to hospital within 2\-12 hours of the onset of myocardial ischemic pain of at least 30 minutes duration
  • 3\. Twelve\-lead electrocardiogram (ECG) reveals one of the following: ST\-segment elevation \* 0\.1 mV in two or more limb leads, or \* 0\.2 mV in two or more contiguous precordial leads indicative of acute myocardial infarction, or left bundle\-branch block
  • 4\. Undergoing PCI for STEMI
  • 5\. LVEF during PCI \< 40%
  • 6\. TIMI flow grade 3 in IRA following reperfusion and stenting

Exclusion Criteria

  • 4\.3 EXCLUSION CRITERIA
  • Subjects having any of the following criteria will not be enrolled in the study:
  • 1\. History of prior myocardial infarction
  • 2\. Prior history of heart failure, left ventricular dysfunction or cardiomyopathy
  • 3\. Active or suspected neoplasia
  • 4\. Known impaired liver function
  • 5\. Cardiogenic shock (SBP\<80mm Hg requiring pressors or IABP)
  • 6\. Estimated glomerular filtration rate (eGFR) \< 45 ml/min/1\.73m2
  • 7\. History of hypoglycaemia requiring hospitalisation
  • 8\. History of primary insulin growth factor\-1 deficiency or growth hormone disorders including acromegaly

Outcomes

Primary Outcomes

Not specified

Similar Trials